Life sciences and health tech news roundup: AIlen Institute’s new CEO, AI2’s incubator, and more

ByLois C

Apr 14, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Allen Institute headquarters in Seattle. (Allen Institute Photograph)

The legacy of the late Microsoft co-founder Paul Allen lives on at some of Seattle’s most modern establishments.

This week GeekWire profiled the AI2 incubator, a branch of the Allen Institute for AI (AI2) introduced by Allen in 2013. GeekWire co-founder Todd Bishop explored the earlier and the foreseeable future of the incubator, which is increasingly fostering wellness tech and biotech firms including BirchAI and Modulus Therapeutics.

We also interviewed the new CEO of the Allen Institute, the lifetime sciences counterpart to the AI2. Rui Costa spoke about crew analysis, his determination to diversity, and his watch on the institute’s approach to new market partnerships.

Read through on for this and a lot more life sciences and well being tech protection in the Pacific Northwest from GeekWire and outside of, like a analyze showcasing the Allen Institute’s new visualization resource, the “Simularium Viewer.”

— Within the AI2 Incubator: Microsoft co-founder’s unfinished legacy fuels quest for new AI startups

The neural dynamics of teamwork: New Allen Institute CEO on diversity and impact in lifestyle science

Seattle startup raises $9.7M for scientific trial to test inhaled CBD as anxiety remedy

The Allen Institute’s “Simularium Viewer” displays a purple nanoparticle about to be enveloped by a yellow lipid coat. See video in this article. (Allen Institute Image)

New studies:

  • The Allen Institute’s “Simularium Viewer” allows computational visualization of biological processes and was described in a analyze this week. Scientists showcased movie simulations of a nanoparticle wrapped by an outer coat, a lung contaminated by the COVID-19 virus, and the bacterium E. Coli dividing.
  • Alpine Immune Sciences revealed a preclinical examine on its guide immuno-oncology candidate, an immune “checkpoint inhibitor” directed against 3 targets at at the time. The Seattle biotech business is tests the compound in two clinical trials.
  • Scientists at Fred Hutch and their colleagues uncovered that breast cancer therapy may well outcome in an elevated threat for cardiovascular events. “Scientists and clinicians should prioritize research that will minimize this threat,” stated Fred Hutch investigator Heather Greenlee in a information launch.
  • A noninvasive ultrasound strategy tested by University of Washington surgeon Jonathan Harper and his colleagues can dissipate kidney stones. The method may direct to considerably less invasive treatment method methods and is licensed to Silicon Valley organization SonoMotion.  

Elevating resources:

  • The University of Washington will establish a new tuberculosis investigate centre with up to $5.3 million from the U.S. Nationwide Institutes of Health and fitness, declared this week.
  • AVM Biotechnology landed a $1.6 million modest business enterprise grant from the National Institutes of Health and fitness. The grant will assistance preclinical investigate on the Seattle company’s lead compound, primarily based on the corticosteroid dexamethasone. The compound triggers a specific type of T cell and will be tested in type 1 diabetic issues in mouse models. Meanwhile, the organization is enrolling sufferers in a stage 1/2 scientific trial tests the compound in blood cancers.

Fostering startups:

  • The College of Washington Startup Profession & Internship Fair this year was stay and in man or woman. Biotech firms were front and heart.
  • Find Ventures and the Washington State Office of Commerce selected 10 tech startups and founders for its initial “Equitable Innovations Accelerator.” Health tech providers Coltrain, Litesprite and GoldenSHERPA built the slash.

Moving up and overseas:

  • Fred Hutch investigator Phil Greenberg was elected president of the American Affiliation for Cancer Analysis.
  • Seattle biotech enterprise Nanostring is expanding, opening a European headquarters in Amsterdam.
  • Adaptive Biotechnologies’ former main health care officer Lance Baldo has a new job with the similar title at South San Francisco-dependent Freenome.
  • Inventprise has a new CEO, Yves Leurquin, and two new board customers. The Redmond, Clean.-based company also obtained $30 million of up to $90 million pledged by the Invoice & Melinda Gates Basis to support clinical growth of the company’s vaccine for pediatric pneumococcal ailment.

By Lois C